Article

Knee cartilage loss in symptomatic knee osteoarthritis over 4.5 years

Department of Epidemiology and Preventive Medicine, Monash University-Central and Eastern Clinical School, Alfred Hospital, Commercial Road, Melbourne, VIC 3004, Australia.
Arthritis research & therapy (Impact Factor: 4.12). 02/2006; 8(4):R90. DOI: 10.1186/ar1962
Source: PubMed

ABSTRACT The objective of this study was to describe the rate of change in knee cartilage volume over 4.5 years in subjects with symptomatic knee osteoarthritis (OA) and to determine factors associated with cartilage loss. One hundred and five subjects were eligible for this longitudinal study. Subjects' tibial cartilage volume was assessed by magnetic resonance imaging (MRI) at baseline, at 2 years and at 4.5 years. Of 105 subjects, 78 (74%) completed the study. The annual percentage losses of medial and lateral tibial cartilage over 4.5 years were 3.7 +/- 4.7% (mean +/- SD; 95% confidence interval 2.7 to 4.8%) and 4.4 +/- 4.7% (mean +/- SD; 95% confidence interval 3.4 to 5.5%), respectively. Cartilage volume in each individual seemed to track over the study period, relative to other study participants. After multivariate adjustment, annual medial tibial cartilage loss was predicted by lesser severity of baseline knee pain but was independent of age, body mass index and structural factors. No factors specified a priori were associated with lateral cartilage volume rates of change. Tibial cartilage declines at an average rate of 4% per year in subjects with symptomatic knee OA. There was evidence to support the concept that tracking occurs in OA. This may enable the prediction of cartilage change in an individual. The only significant factor affecting the loss of medial tibial cartilage was baseline knee pain, possibly through altered joint loading.

0 Followers
 · 
125 Views
  • Source
    • "In addition, the damage it purports to measure may be as much in the meniscus as in the hyaline cartilage (Hunter et al. 2006). More recently magnetic resonance imaging (MRI) measurements of medial tibiofemoral cartilage thickness and volume have been shown in several centres (Eckstein et al. 2006; Wluka et al. 2006) to decline typically by 4% per annum in OA patients. Reproducibility varies between different centres and in different settings, but coefficients of variation of 2–4% are typical (Eckstein et al. 2006). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The objective was to assess the effect of doxycycline treatment on a magnetic resonance imaging (MRI) biomarker of cartilage volume loss, and on matrix metalloproteinase (MMP) activity in a guinea pig osteoarthritis model. Guinea pigs (9 months old) were dosed with vehicle or doxycycline, 0.6, 3.0 mg/kg/day for 66 days. Fat-suppressed 3D gradient-echo MRI of the left knee was acquired pre- and post dosing. Change in medial tibial plateau (MTP) cartilage volume (MT.VC) was determined using image analysis. At termination, MTP cartilage was removed from knees and proteolytic MMP activity determined using a fluorescent peptide substrate assay. Vehicle-treated animals lost 20.5% (95% CI mean 25.6-15.1) MT.VC. The doxycycline (0.6 mg/kg/day) group lost 8.6% (P < 0.05, 95% CI 20.6 to -5.3) whilst the 3.0 mg/kg/day group lost 10.0% (P < 0.05, 95% CI 13.9-6.0%). Endogenous levels of active MMPs were below limits of detection in all samples. However, doxycycline treatment ablated amino phenyl mercuric acid activated MMP-13 and MMP-8 levels, reduced MMP-9 levels by 65% and MMP-1 levels by 24%. Doxycycline treatment resulted in partial protection from MT.VC loss and was associated with complete reduction in MMP-13 and MMP-8, and partial reduction in MMP-9 activity. These data imply a role of MMPs in cartilage degeneration but incomplete protection suggests that additional doxycycline insensitive mechanisms are important in this model. The protective effect of doxycycline correlates with the clinical finding of lessened joint space narrowing, strengthens the utility of this animal model in identifying disease-modifying osteoarthritic drugs and supports the use of MRI biomarkers of cartilage loss.
    International Journal of Experimental Pathology 05/2009; 90(2):174-81. DOI:10.1111/j.1365-2613.2008.00634.x · 2.05 Impact Factor
  • Source
    Arthritis & Rheumatology 03/2006; 54(3):1027; author reply 1028. DOI:10.1002/art.21665 · 7.87 Impact Factor
  • Source
    Arthritis & Rheumatology 03/2006; 54(3):1026-7. DOI:10.1002/art.21676 · 7.87 Impact Factor
Show more